Detalhe da pesquisa
1.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet
; 403(10427): 632-644, 2024 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38246194
2.
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
N Engl J Med
; 383(12): 1139-1148, 2020 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877599
3.
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
J Transl Med
; 21(1): 753, 2023 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37880788
4.
Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.
Acta Haematol
; 146(2): 166-171, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273464
5.
Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey.
Qual Life Res
; 32(12): 3531-3545, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37522941
6.
Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy.
Curr Oncol Rep
; 24(10): 1273-1280, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35639333
7.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 643-654, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857412
8.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 655-664, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857414
9.
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
Br J Cancer
; 124(3): 574-580, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33087895
10.
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
N Engl J Med
; 378(19): 1789-1801, 2018 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658430
11.
Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A real-world study.
Pharmacoepidemiol Drug Saf
; 30(10): 1371-1379, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33840147
12.
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
Lancet Oncol
; 21(3): 358-372, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32007138
13.
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 21(11): 1465-1477, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961119
14.
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
N Engl J Med
; 377(19): 1813-1823, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28891408
15.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
N Engl J Med
; 377(19): 1824-1835, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28891423
16.
Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
BMC Nephrol
; 21(1): 391, 2020 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32894101
17.
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(5): 701-710, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30928620
18.
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Lancet Oncol
; 19(5): 672-681, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29602646
19.
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.
Br J Cancer
; 118(6): 777-784, 2018 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29438370
20.
Nivolumab in previously untreated melanoma without BRAF mutation.
N Engl J Med
; 372(4): 320-30, 2015 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-25399552